Broadcast Date: 
  • Time: 

Lentiviral vectors, commonly produced by transient lentiviral plasmid transfection, are a popular choice for the development of cell therapies. However, packaging and producer cell lines, which have elements of the lentiviral packaging system already embedded in the cells’ genome, offer an attractive alternative to transient transfection for large scale clinical or commercial lentiviral manufacture.

Using packaging or producer cell lines reduces or eliminates the need for plasmid transfection, which not only decreases process complexity, and so reduces the risk of batch to batch variation or human error, but also significantly decreases the cost of goods associated with the large-scale manufacture of lentiviral vectors and simplifies the process of scaling up.

In this GEN webinar, Dr. Qian Liu will discuss a novel strategy for stable lentiviral cell line development and show recent data demonstrating the robustness of the lentiviral packaging and producer cell lines from OXGENE.

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelist.

Produced with support from:

Oxgene logo
Qian Liu, PhD Senior Group Leader, OXGENE
Qian Liu, PhD
Senior Group Leader
Previous articleResearchers Discover Why ApoE4 Increases the Risk of Alzheimer’s Disease
Next articleEngineering the Immune Response for Therapeutic Success